Grid Oasis
S&P 500NASDAQ 100Dow JonesRussell 2000All StocksSectors & Industries

CRVO

+ Watchlist+ Portfolio

CervoMed Inc.

Regulated industrySells to businessesDevelopment stageTags from an AI model reading the company description.
GridBrain

GridBrain — Sign in

GridSentinel

GridSentinel — Sign in

GridAegis

GridAegis — Sign in

Key Metrics

Previous Close
$1.50
52-Week Range
$1.27 – $10.00
Market Cap
$21.94M
P/E (TTM)
—
EPS (TTM)
-2.65
Dividend Yield
0.00%
Advanced Metrics
Price/Book
1.26
PEG Ratio
—
Return on Equity
-131.52%
Return on Assets
-70.33%
Gross Margin
0.00%
Operating Margin
-334924.88%
Profit Margin
0.00%
Current Ratio
5.37
Debt/Equity
—
Total Debt
$0.00
Free Cash Flow
$-15.99M
Revenue Growth
—
Earnings Growth
—
Enterprise Value
$2.34M

Market Snapshot

About

CervoMed Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for neurodegenerative diseases. Headquartered in Rockville, Maryland, the company is advancing neflamapimod, a selective p38 alpha kinase inhibitor, as a potential therapy for dementia with Lewy bodies (DLB) and other neurological conditions. CervoMed's drug candidate targets neuroinflammation, a key factor in neurodegenerative disease progression. The company was formerly known as Cerevance and rebranded following its strategic focus on neflamapimod development.